Contact Details
Home
About CuroVax
Company Profile
Company Culture
Factory Snapshots
Products & Services
Vaccine
Logistics Distribution
Information Disclosure
Adverse Reaction
Policy & News
Policies and regulations
Industry News
Company News
R&D & Innovation
R&D Platform
Products in Development
Quality Control
Quality Management System
Join Us
Recruitment
Contact
Language
中文
English
2022
2023-04-27
Establishment of a wholly-owned subsidiary, "Runtaiyi".
2021
NDA submission for "Lyophilised Human Rabies Vaccine (Vero Cell)" project was accepted. The project of "Tetravalent Influenza Virus Lysate Vaccine" was approved for clinical trial.
2019
Establishment of the project "Tetravalent Influenza Virus Lysing Vaccine".
2017
"Completion of Phase III Clinical Trial of Lyophilised Human Rabies Vaccine (Vero Cell) Project
2014
The project "Lyophilised Human Rabies Vaccine (Vero Cell)" obtained clinical trial approval.
2013
Received GMP certificate for "Influenza virus lysate vaccine" project.
Fax：0519-81668927 Email：contact@curovax.net
[Follow public number]
State Drug Administration (SDA)
China Institute for Food and Drug Control (CIFDC)
Chinese Centre for Disease Control and Prevention (CDC)
WHO
NIBSC
ATCC
Jiangsu Provincial Drug Administration
©2023 Jiangsu CuroVax Co., Ltd IPV6 Powered by www.300.cn | tabs
